



Proteon's Expanded Access Policy

Proteon Therapeutics is committed to improving the lives of patients and families affected by kidney and vascular diseases. Expanded access to certain therapies is important. We consider a number of factors in evaluating when it would be appropriate to provide expanded access to our investigational therapies. These include:

- the illness must be serious or life-threatening with no other satisfactory treatment options (such as approved products or enrolling clinical trials); and
- whether granting expanded access would potentially compromise the scientific validity of broader development programs, or interfere with or delay current clinical trials or regulatory filings designed to make the therapy available to many more patients.

Proteon's lead clinical candidate, vonapanitase, is not currently available outside of the clinical trial setting. While clinical trials are ongoing, we believe that participation in one of these studies remains the safest and most appropriate way to access vonapanitase. If you have any questions, please speak with your physician or contact expandedaccess@proteontx.com. We anticipate acknowledging receipt of any requests sent to this email within five business days.

In accordance with the [21st Century Cures Act](#), Proteon Therapeutics may revise this policy at any time. This policy will be updated with a hyperlink or other reference to the expanded access record on clinicaltrials.gov after such record becomes active.